These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37306812)

  • 1. Spondyloarthritis mass cytometry immuno-monitoring: a proof of concept study in the tight-control and treat-to target TiCoSpA trial.
    Koppejan H; Beyrend G; Hameetman M; Abdelaal T; Toes REM; van Gaalen FA
    Clin Rheumatol; 2023 Sep; 42(9):2387-2396. PubMed ID: 37306812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
    Kroon FP; van der Burg LR; Ramiro S; Landewé RB; Buchbinder R; Falzon L; van der Heijde D
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010952. PubMed ID: 26186173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ankylosing spondylitis and non-radiographic axial spondyloarthritis in a multi-ethnic Asian population of Singapore.
    Hong C; Kwan YH; Leung YY; Lui NL; Fong W
    Int J Rheum Dis; 2019 Aug; 22(8):1506-1511. PubMed ID: 31090201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating mature granzyme B+ T cells distinguish Crohn's disease-associated axial spondyloarthritis from axial spondyloarthritis and Crohn's disease.
    Lefferts AR; Regner EH; Stahly A; O'Rourke B; Gerich ME; Fennimore BP; Scott FI; Freeman AE; Jones K; Kuhn KA
    Arthritis Res Ther; 2021 May; 23(1):147. PubMed ID: 34022940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?
    Maksymowych WP; Inman RD; Bessette L; Rahman P; Rampakakis E; Asin-Milan O; Rachich M; Marrache AM; Lehman AJ
    Arthritis Res Ther; 2023 Apr; 25(1):70. PubMed ID: 37118833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry.
    Bodur H; Yurdakul FG; Ataman S; Cay HF; Gurer G; Capkin E; Sezer İ; Duruoz MT; Melikoglu MA; Rezvani A; Yagci I; Gogus F; Kamanli A; Akgul O; Cevik R
    Clin Rheumatol; 2022 Jul; 41(7):2053-2063. PubMed ID: 35353263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
    Kilic E; Kilic G; Akgul O; Ozgocmen S
    Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
    Malaviya AN; Kalyani A; Rawat R; Gogia SB
    Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
    Braun J; Kiltz U; Baraliakos X
    Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of remission in people with axial spondyloarthritis: A systematic literature review.
    Pinto AS; Farisogullari B; Machado PM
    Semin Arthritis Rheum; 2022 Oct; 56():152078. PubMed ID: 35944350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
    Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
    Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of axial spondyloarthritis patients in China: results from ChinaSpA, the Chinese Spondyloarthritis Registry.
    Su J; Wang R; Duan X; Wang Y; Wu Z; Yang M; Xu J; Fan W; Zhao C; Li Q; Wang X; Zhu J; Wu L; Li M; Zeng X
    Clin Exp Rheumatol; 2022 Mar; 40(3):544-550. PubMed ID: 33938794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis.
    Sagard J; Olofsson T; Mogard E; Marsal J; Andréasson K; Geijer M; Kristensen LE; Lindqvist E; Wallman JK
    Arthritis Res Ther; 2022 Feb; 24(1):42. PubMed ID: 35151357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of active inflammation, chronic structural damage, and response to treatment of sacroiliitis in axial spondyloarthritis using the Spondyloarthritis research consortium of Canada scoring system.
    Zhang Y; Guo Z; Zhan Y; Qu J; Lei X
    BMC Musculoskelet Disord; 2022 Jul; 23(1):654. PubMed ID: 35804360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of circulating lymphocyte subsets with response to IL17i and TNFi in axial spondyloarthritis.
    Rabin T; De Marco G; Dubash SR; Shuweihdi F; Marzo-Ortega H; Emery P; Ponchel F; Goeb V
    Clin Exp Rheumatol; 2023 Mar; 41(3):694-703. PubMed ID: 35819806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of extracellular matrix metabolites are associated with changes in Ankylosing Spondylitis Disease Activity Score and MRI inflammation scores in patients with axial spondyloarthritis during TNF inhibitor therapy.
    Holm Nielsen S; Sun S; Bay-Jensen AC; Karsdal M; Sørensen IJ; Weber U; Loft AG; Kollerup G; Thamsborg G; Madsen OR; Møller J; Østergaard M; Pedersen SJ
    Arthritis Res Ther; 2022 Dec; 24(1):279. PubMed ID: 36564778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.